August 2024 - Page 3 of 3 - BioMedWire (BMW)

WednesdayAug 07, 2024 10:00 am

Snycio, Vevol Media Partner to Transform eCommerce Store Management

Recently, Syncio entered into a partnership agreement with Vevol Media to streamline e-commerce operations for businesses by integrating different sales channels. Syncio has, for a while now, been streamlining e-commerce operations for merchants on WooCommerce and Shopify. The company is focused on efficiency and simplicity, while Vevol Media specializes in assisting businesses to thrive in the digital marketplace. Vevol, a leading partner of Shopify, provides a comprehensive range of services, including Shopify design, development, support and marketing. This partnership is a huge step forward in the e-commerce space, combining Vevol’s Shopify expertise and Syncio’s synchronization tech. It will help deliver…

WednesdayAug 07, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Subsidiary BayMedica Releases Market Report for 2023 on “Minor Cannabinoids”

The report explores the growth, competition, and consumer trends, for lesser known cannabinoids The report highlights a 5.4% revenue increase in the edible market for 2023, with total sales reaching $2.097 billion As consumer preferences shift towards edibles for their therapeutic effects and consistent experiences, the industry product landscape is set to evolve With the increasing acceptance of cannabis use in society, the popularity of edibles—products containing cannabinoids that can be consumed as food or drink—has surged. While many consumers are familiar with edibles containing THC (tetrahydrocannabinol), known for its euphoric effects, or CBD (cannabidiol), recognized for its therapeutic benefits,…

TuesdayAug 06, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Advances Neurodegenerative Disease Treatment with Innovative Nanotherapeutics

Clene is developing a new class of drugs that hold the potential to transform the lives of millions suffering from debilitating conditions such as Amyotrophic Lateral Sclerosis (“ALS”), Multiple Sclerosis (“MS”), and Parkinson’s Disease (“PD”) CNM-Au8(R), Clene’s lead drug candidate, is a fundamentally new approach for treating the underlying factors contributing to ALS, MS, and PD, by restoring neuronal health and function ALS, the most prevalent adult-onset progressive motor neuron disease, affects approximately 30,000 people in the U.S. Clene (NASDAQ: CLNN), a pioneering biopharmaceutical company, is making significant strides in the treatment of neurodegenerative diseases through its novel nanotherapeutic platform.…

MondayAug 05, 2024 10:00 am

Study Uncovers How Brain Tumors Evolve During Treatment

Glioblastoma multiforme is one of the most common brain cancers, primarily affecting an individual’s spine and/or brain. This malignant tumor forms from astrocytes, which support nerve cells. These tumors usually grow and spread very quickly, which creates pressure and destroys healthy tissue. In 2008, the glioblastoma multiforme genome was characterized by the Cancer Genome Atlas. Since then, scientists have directed their efforts toward examining transcriptomic and genomic data for new therapeutic targets that will improve patient clinical outcomes. Despite this, the five-year survival rates for this aggressive cancer remain below 5%. In a new study, scientists recently demonstrated how brain…

FridayAug 02, 2024 10:00 am

Data Gaps Which Need to Be Filled in Medicare Advantage

All beneficiaries of Medicare can enroll in Medicare Advantage as an alternative if they need private insurance. Currently, Medicare Advantage makes up over one-half all individuals enrolled in Medicare. Estimates from the Center for American progress show that the Centers for Medicare and Medicaid Services overpays Medicare Advantage plans by between 22% to 39%. This year, overpayments total between $83 billion and $127 billion. This is despite the fact that there’s no substantial evidence that this program promotes health equity for its enrollees or enhances health-care quality. Considering this, there is need for the Centers for Medicare and Medicaid Services…